Status:
TERMINATED
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
Lead Sponsor:
Bayer
Conditions:
Metastatic Castration-resistant Prostate Cancer
Bone Metastases
Eligibility:
MALE
Brief Summary
This is an observational study in which data from Chinese men with metastatic castration-resistant prostate cancer that has spread to the bones and who start Radium-223 therapy is studied. When tumor...
Eligibility Criteria
Inclusion
- Male patient
- Histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases
- No visceral metastases
- Decision to initiate treatment with Radium-223 was made independently prior to patient enrollment in the study as per investigator's routine treatment practice
- Signed informed consent
Exclusion
- Patients previously treated with Radium-223 for any reason
- Patients currently treated in any other clinical trials including other Radium-223 studies
- Patients are planned for the systemic concomitant use of other radiopharmaceuticals for treatment of prostate cancer or for other use
- Participation in an investigational program with interventions outside of routine clinical practice
- Patients previously treated with Docetaxel
- Patients under treatment with Abiraterone Acetate and the Corticosteroids Prednisone or Prednisolone
- Besides Inclusion and exclusion criteria, sites should also follow the locally approved Radium-223 product information
Key Trial Info
Start Date :
September 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT05301062
Start Date
September 15 2022
End Date
June 30 2023
Last Update
September 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many locations
Multiple Locations, China